

Elizabeth L Berkow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12120272/publications.pdf>

Version: 2024-02-01

44
papers

5,448
citations

159358

30
h-index

233125

45
g-index

47
all docs

47
docs citations

47
times ranked

4139
citing authors

#	ARTICLE	IF	CITATIONS
1	Simultaneous Emergence of Multidrug-Resistant <i>Candida auris</i> on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. <i>Clinical Infectious Diseases</i> , 2017, 64, 134-140.	2.9	1,099
2	Azole Antifungal Resistance in <i>Candida albicans</i> and Emerging Non- <i>albicans</i> <i>Candida</i> Species. <i>Frontiers in Microbiology</i> , 2016, 7, 2173.	1.5	531
3	Changes in the epidemiological landscape of invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, i4-i13.	1.3	349
4	Fluconazole resistance in <i>Candida</i> species: a current perspective. <i>Infection and Drug Resistance</i> , 2017, Volume 10, 237-245.	1.1	346
5	Genomic insights into multidrug-resistance, mating and virulence in <i>Candida auris</i> and related emerging species. <i>Nature Communications</i> , 2018, 9, 5346.	5.8	298
6	<i>Candida auris</i> : The recent emergence of a multidrug-resistant fungal pathogen. <i>Medical Mycology</i> , 2019, 57, 1-12.	0.3	280
7	Tracing the Evolutionary History and Global Expansion of <i>Candida auris</i> Using Population Genomic Analyses. <i>MBio</i> , 2020, 11, .	1.8	224
8	Gain-of-Function Mutations in <i>UPC2</i> Are a Frequent Cause of <i>ERG11</i> Upregulation in Azole-Resistant Clinical Isolates of <i>Candida albicans</i> . <i>Eukaryotic Cell</i> , 2012, 11, 1289-1299.	3.4	207
9	Multiple introductions and subsequent transmission of multidrug-resistant <i>Candida auris</i> in the USA: a molecular epidemiological survey. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1377-1384.	4.6	204
10	Investigation of the First Seven Reported Cases of <i>Candida auris</i> , a Globally Emerging Invasive, Multidrug-Resistant Fungus – United States, May 2013–August 2016. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 1234-1237.	9.0	201
11	Antifungal Susceptibility Testing: Current Approaches. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	138
12	Molecular Epidemiology of <i>Candida auris</i> in Colombia Reveals a Highly Related, Countrywide Colonization With Regional Patterns in Amphotericin B Resistance. <i>Clinical Infectious Diseases</i> , 2019, 68, 15-21.	2.9	132
13	Notes from the Field: Ongoing Transmission of <i>Candida auris</i> in Health Care Facilities – United States, June 2016–May 2017. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 514-515.	9.0	124
14	Population-Based Active Surveillance for Culture-Confirmed Candidemia – Four Sites, United States, 2012–2016. <i>MMWR Surveillance Summaries</i> , 2019, 68, 1-15.	18.6	111
15	Mutations in <i>TAC1B</i> : a Novel Genetic Determinant of Clinical Fluconazole Resistance in <i>Candida auris</i> . <i>MBio</i> , 2020, 11, .	1.8	101
16	<i>Candida auris</i> for the Clinical Microbiology Laboratory: Not Your Grandfather's <i>Candida</i> Species. <i>Clinical Microbiology Newsletter</i> , 2017, 39, 99-103.	0.4	86
17	Activity of CD101, a long-acting echinocandin, against clinical isolates of <i>Candida auris</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 196-197.	0.8	82
18	<i>In Vitro</i> Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of <i>Candida auris</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	80

#	ARTICLE	IF	CITATIONS
19	Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in <i>Candida parapsilosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5942-5950.	1.4	75
20	Isolation of <i>Candida auris</i> from 9 patients in Central America: Importance of accurate diagnosis and susceptibility testing. <i>Mycoses</i> , 2018, 61, 44-47.	1.8	74
21	Pharmacodynamic Optimization for Treatment of Invasive <i>Candida auris</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	65
22	<i>UPC2</i> Is Universally Essential for Azole Antifungal Resistance in <i>Candida albicans</i> . <i>Eukaryotic Cell</i> , 2014, 13, 933-946.	3.4	58
23	The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates <i>In Vitro</i> and <i>In Vivo</i> Activity against <i>Candida auris</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	53
24	Activity of novel antifungal compound APX001A against a large collection of <i>Candida auris</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3060-3062.	1.3	47
25	Identification of <i>Candida auris</i> by Use of the Updated Vitek 2 Yeast Identification System, Version 8.01: a Multilaboratory Evaluation Study. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	47
26	Isolation of azole-resistant <i>Aspergillus fumigatus</i> from the environment in the south-eastern USA. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2443-2446.	1.3	46
27	Disruption of the Transcriptional Regulator Cas5 Results in Enhanced Killing of <i>Candida albicans</i> by Fluconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6807-6818.	1.4	45
28	Detection of TR ₃₄ /L98H <i>CYP51A</i> Mutation through Passive Surveillance for Azole-Resistant <i>Aspergillus fumigatus</i> in the United States from 2015 to 2017. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	40
29	Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of <i>Candida auris</i> Infections. <i>Antibiotics</i> , 2020, 9, 539.	1.5	38
30	Multidrug-Resistant <i>Aspergillus fumigatus</i> Carrying Mutations Linked to Environmental Fungicide Exposure – Three States, 2010–2017. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 1064-1067.	9.0	38
31	Ceragenins are active against drug-resistant <i>Candida auris</i> clinical isolates in planktonic and biofilm forms. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1537-1545.	1.3	24
32	Understanding the Emergence of Multidrug-Resistant <i>Candida</i> : Using Whole-Genome Sequencing to Describe the Population Structure of <i>Candida haemulonii</i> Species Complex. <i>Frontiers in Genetics</i> , 2020, 11, 554.	1.1	24
33	Emerging Multidrug-Resistant <i>Candida duobushaemulonii</i> Infections in Panama Hospitals: Importance of Laboratory Surveillance and Accurate Identification. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	22
34	Evaluation of nine surface disinfectants against <i>Candida auris</i> using a quantitative disk carrier method: EPA SOP-MB-35. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1219-1221.	1.0	22
35	<i>In Vitro</i> Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 378.	1.5	19
36	Bloodstream Infections With <i>Candida auris</i> Among Children in Colombia: Clinical Characteristics and Outcomes of 34 Cases. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 151-154.	0.6	18

#	ARTICLE	IF	CITATIONS
37	Antifungal activity of nikkomycin Z against <i>Candida auris</i> . Journal of Antimicrobial Chemotherapy, 2021, 76, 1495-1497.	1.3	17
38	Genomic Diversity of Azole-Resistant <i>Aspergillus fumigatus</i> in the United States. MBio, 2021, 12, e0180321.	1.8	17
39	Rapid Assessment and Containment of <i>Candida auris</i> Transmission in Postacute Care Settings—Orange County, California, 2019. Annals of Internal Medicine, 2021, 174, 1554-1562.	2.0	17
40	<i>Candida parapsilosis</i> Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	9
41	Performance Evaluation of Culture-Independent SYBR Green <i>Candida auris</i> Quantitative PCR Diagnostics on Anterior Nares Surveillance Swabs. Journal of Clinical Microbiology, 2020, 58, .	1.8	6
42	Categorizing Susceptibility of Clinical Isolates of <i>Candida auris</i> to Amphotericin B, Caspofungin, and Fluconazole by Use of the CLSI M44-A2 Disk Diffusion Method. Journal of Clinical Microbiology, 2021, 59, .	1.8	6
43	Antifungal Susceptibility Testing: The Times They Are A-Changing. Clinical Microbiology Newsletter, 2019, 41, 85-90.	0.4	2
44	Hot Topics in Antifungal Susceptibility Testing: a New Drug, a Bad Bug, Sweeping Caspofungin Testing under the Rug, and Solving the Epidemiological Cutoff Value Shrug. Clinical Microbiology Newsletter, 2016, 38, 103-108.	0.4	1